Pancreatic ductal adenocarcinoma is a devastating disease, characterized by a rapid progression and poor treatment response. Using gene expression profiling of pancreatic cancer tissues, we previously identified periostin as a potential diagnostic and therapeutic target. In this study, we report the overexpression of periostin in a larger set of pancreatic cancer tissues and show that although the periostin transcript is exclusively expressed in tumour cells, the protein product is only detected in the extracellular matrix adjacent to cancer cells. Using an enzyme-linked immunosorbent assay (ELISA) assay, we show significantly increased levels of periostin in the sera of pancreatic cancer patients compared to non-cancer controls. We demonstrate that periostin promotes the invasiveness of tumour cells by increasing the motility of cells without inducing expression of proteases, and enhances the survival of tumour cells exposed to hypoxic conditions. At the molecular level, we provide evidence that the a 6 b 4 integrin complex acts as the cell receptor of periostin in pancreatic cancer cells and that interaction promotes phosphorylation of focal adhesion kinase (FAK) and protein kinase B (AKT) though activation of the PI3 kinase pathway, but not the RAS/MEK/ERK pathway. These findings suggest an important role of periostin in pancreatic cancer and provide a rationale to study periostin for diagnostic and therapeutic applications.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the industrialized world (Jemal et al., 2003) . This is due to both a paucity of diagnostic tools to detect early stages of the disease and a poor outcome following chemotherapy and radiation therapy even when combined with surgical excision of the tumour (DiMagno et al., 1999) . Therefore, a better understanding of the molecular mechanisms involved in pancreatic cancer progression is urgently needed to identify novel molecular targets for early screening and to develop new therapeutic approaches.
To look for new candidates, our laboratory has recently performed global gene expression profiling studies of PDAC compared with normal pancreatic tissue (Crnogorac-Jurcevic et al., 2003) . Periostin was identified as a potentially promising candidate for involvement in the pathogenesis of this disease and was chosen for further characterization.
Periostin is a secreted 90 kDa protein originally identified as an osteoblast-specific factor preferentially expressed in the periosteum in bone tissues (Takeshita et al., 1993; Horiuchi et al., 1999) . Periostin has a typical signal sequence, followed by a cysteine-rich domain, four repeated and conserved domains and a C-terminal hydrophilic domain (Takeshita et al., 1993; Horiuchi et al., 1999) . A similar structure was reported for fasciclin I, a cell adhesion molecule involved in the development of the central nervous system of insects (Zinn et al., 1988) , and for the big-h3 molecule, a secreted protein induced by TGF-b1 which promotes the attachment and spreading of fibroblasts (Skonier et al., 1992; LeBaron et al., 1995) . Periostin was found to be overexpressed in various types of human cancer such as lung (Sasaki et al., 2001a) , brain (Sasaki et al., 2002) , ovary (Gillan et al., 2002) , breast (Shao et al., 2004) and colon cancers Tai et al., 2005) and elevated levels have been detected in sera of patients with thymoma (Sasaki et al., 2001b) , non-small lung carcinoma (Sasaki et al., 2001c) and breast cancer (Sasaki et al., 2003) . Although these reports implicate periostin in tumour spread, the functional role of this protein is poorly described and recent publications report conflicting data. While one report demonstrated that ectopic expression of periostin enhanced metastatic growth of colon cancer by preventing stress-induced apoptosis in cancer another showed evidence for a potential tumour suppressor function as overexpression of periostin suppressed the invasiveness and metastasis of tumour cells (Kim et al., 2005) . Furthermore, the exact mechanism by which periostin exerts its biological function has remained elusive as in all cancer types tested to date periostin was reported to be localised in the cytoplasm of tumour cells and never in the surrounding stroma, which is surprising for a typically secreted protein sharing significant homology with the big-h3 protein (Gibson et al., 1997; Billings et al., 2002) .
In this study, we investigated the expression and spatial localization of periostin in human pancreatic cancer tissues and tumour cell lines, as well as quantifying periostin levels in a large series of serum samples. We used recombinant periostin to examine the biological role of this protein in two key elements of pancreatic cancer cell biology: malignant invasion and resistance to cell-death. Furthermore, we identified the cell surface receptor of periostin in pancreatic cancer cells and the associated cell-signalling pathway that is likely to contribute to the development of this aggressive cancer.
Results

Overexpression of Periostin in PDAC
We performed quantitative real-time polymerase chain reaction (QRT-PCR) analysis on seven samples of chronic pancreatitis (CP), 17 samples of PDAC, and a pool of five normal pancreatic specimens. The highest periostin expression level was detected in the PDAC group (mean ¼ 49.6) with 35% (6/17) of cases overexpressed periostin more than 50-fold and 12% (2/17) more than 100-fold as compared to the normal group. High level of periostin expression was also detected in the CP group (mean ¼ 20.3) (Figure 1a) .
We next performed an in situ mRNA hybridization on six PDAC tissue samples to identify the exact cellular source of periostin production. Results showed the presence of periostin mRNA in the cytoplasm of cancer cells (Figure 1b, arrows) , whereas the stromal cells surrounding the tumour were completely negative (Figure 1b, arrowheads) . In the three normal pancreatic tissues tested no signal was observed in the ductal, acinar and islet cells (Figure 1b, panel i) .
In sharp contrast, the immunohistochemical analysis of 18 PDAC and six normal pancreatic tissues showed an inverse pattern of periostin localization. Periostin protein was mainly detected in the juxtatumoral stroma components and/or at the contact points with the tumour cell membranes (Figure 1c, arrows) . The tumour cells themselves showed no immunoreactivity except for occasional weak intracytoplasmic staining. In addition, all of the six normal pancreatic cases tested were negative or showed only faint immunoreactivity, mainly restricted to the cytoplasm of acinar cells (Figure 1c , panel i).
Elevated serum periostin levels detected in patients with PDAC As shown in Figure 1d, Periostin expression in other cancer tissues Using a multiple cancer tissue microarray, we found that breast and pancreatic cancers showed the highest level of periostin expression followed by colon, larynx and liver cancer tissues (Figure 2 ). Weak or no periostin protein expression was observed in all matched normal specimens with the exception of the normal gastric tissues where significant immunoreactivity was observed (Figure 2a) . The tissue distributions of the periostin mRNA and protein were similar to those observed in PDAC tissues with localisation of periostin mRNA in the cytoplasm of cancer cells and periostin protein in peritumoral stroma (Figure 2b ).
Expression of periostin in PDAC cell lines
We next examined the expression of periostin in a panel of pancreatic cancer cell lines. Results from RT-PCR and western-blot analysis (Figure 3a ) revealed the absence of periostin expression at both transcriptional and protein level in all of the eight PDAC cell lines tested. Moreover, addition in culture of the proinflammatory molecules TGFb, FGFa and PMA, and coculture with NIH3T3 fibroblasts or pancreatic stellate cells were insufficient to induce periostin expression in vitro (Figure 3b and c) . Culture of the cells on Matrigel-coated wells or under hypoxic conditions also failed to induce endogenous periostin expression (data not shown). In addition, the subcutaneous implantation of Panc1 cells to form xenograft tumours in mice did not result in immunohistochemically detectable induction of periostin in the tumour cells nor in the juxtatumoral stromal compoments (data not shown). Conversely, transfection of 293 cells with PN cDNA allowed detection of periostin protein mainly in the conditioned media of the cells (Figure 3a , bottom panel) and to a lesser degree in the cell lysate fraction (data not shown), confirming that periostin is a secreted protein. The finding that periostin is not expressed by any of the PDAC cell lines is surprising and not understood at this moment.
Role of periostin in the invasion of PDAC cells
Because immunohistochemical analysis showed expression of periostin at the invading margin of pancreatic cancer deposits (Figure 1c, arrows) we investigated the role of periostin in the invasive capacity of tumour cells in vitro.
For these assays, we purified the secreted form of periostin produced in a baculovirus expression system (Figure 3d ). Results from matrigel invasion assay showed a dose-dependent increase in the rate of invasion of CFPac-1 cells (Figure 4a ) and Panc-1 (data not shown) when increasing concentrations of rPN were used. To determine whether the effect of periostin on the invasion of PDAC cells was linked to overexpression of proteases we carried out a gelatin zymography assay. As shown in Figure 4b , the expression of MMP-2 and MMP-9 was detected in the supernatant of CFPac1 cells but no difference was observed between the untreated and periostin-treated cells. Similar results were obtained with Panc-1 cells (data not shown). To evaluate the possibility that other proteases could be involved in the rPN-induced invasion of PDAC cells, we interrogated a small gene GEArray that includes 13 different proteases and their respective inhibitors. As shown in Figure 4c , no difference in the intensity of spots was evident between the untreated and periostin-treated samples.
Recent reports have shown that periostin interacts with the a v b 3 integrin in tumour cells (Gillan et al., 2002; Bao et al., 2004) and as a v b 3 integrin is known to regulate the expression of proteases, we next sought to determine the effect of overexpression of the a v b 3 in CFPac1 cells on the induction of proteases induced by periostin. The a v -positive CFPac1 cells were infected with a b 3 integrin-expressing retrovirus (Morgan et al., 2004) and elevated expression of the a v b 3 integrin complex confirmed by flow cytometry (Figure 4d, left  panel) . Surprisingly, treatment of these cells with rPN did not change expression of the proteases as shown by gelatin zymography (Figure 4d , right panel) and gene array (data not shown).
Periostin promotes the invasion of CFPac1 cells by increasing motility and FAK phosphorylation Invasion through matrigel matrix is a three-step process involving adhesion, migration and the expression of proteases. Therefore, to elucidate the underlying cellular mechanisms involved in the invasion of PDAC, we investigated the effect of rPN on the adhesion and migration of CFPac1 cells.
Our results show that periostin acts as an adhesion molecule able to promote the attachment of CFPac1 cells (Figure 5a ) to the same level as a fibronectin Periostin promotes invasion and survival in pancreatic cancer P Baril et al substrate (data not shown). In the presence of antiperiostin antibody, adhesion was inhibited by 70%. To identify the cell surface receptor for periostin in PDAC cells, we pre-treated the cells with blocking antibodies directed against different integrin subunits. As shown in Figure 5a , the anti-b 4 antibody partially blocks (40% of control, Po0.05) attachment of the cell to periostincoated wells whereas the anti-a v b 3 , -a v b 5 , -a v b 6 antibodies had no effect ( Figure 5a and Supplementary Figure 1S ). In addition, although the anti-b 1 integrin antibody binds strongly to the CFPac-1 cells (Figure 4d ), this antibody did not affect attachment of cells (Figure 5a ), excluding the possibility of a nonspecific effect of the anti-b 4 antibody on the attachment of cells to periostin by steric hindrance. In order to support the finding that the b 4 integrin subunit promotes attachment of cells to periostin, we looked at the effect of silencing of the b 4 integrin on adhesion of the cells to periostin-coated wells. As shown in Supplementary Figure 2SA , a 60% reduction in the level of expression of the b 4 integrin was detected after treatment with the anti-b 4 siRNA oligonucleotides whereas expression of the b 1 , b 3 and b 5 integrin subunits remained unchanged (data not shown). Treatment of the cells with the control siRNA oligonucleotides had no effect on expression of the b 4 integrin and other integrin subunits (data not shown). Interestingly, when the b 4 siRNA-treated cells were plated on periostin-coated wells, a reduction of up to 40% in adhesion level on periostin was detected (Supplementary Figure 2Sb) . This inhibition could be increased to 65% of the control when the same cells were treated with the anti-b 4 blocking antibody before plating on periostin-coated wells (Supplementary Figure 2Sb) . This last treatment was used to block the adhesive activity of the remaining integrin complex in b 4 siRNA-treated cells. In contrast, treatment of CFPac1 cells with the control siRNA oligonucleotide did not change adhesion of cells to periostin, demonstrating the specificity of our results.
We next investigated the role of periostin in the migration of CFPac1 cells by using a chemotaxis assay. Similar to the invasion assay, the results in Figure 5b show a remarkable increase in cell migration of CFPac-1 with increasing concentrations of rPN. Interestingly, treatment of cells with an anti-b 4 antibody before stimulation with rPN significantly reduced (60% of control, Po0.05) the number of migrated cells (Figure 5b ) whereas an IgG control antibody had no effect (data not shown). Finally, we looked at the phosphorylation status of the tyrosine 397 of FAK as a marker of integrin signalling and cell spreading. Results from Western-blot analysis (Figure 5c ) demonstrated an increasing level of FAK phosphorylation when the cells were exposed to periostin-coated dishes. Maximum FAK phosphorylation was detected after 90 min of adhesion corresponding to the time when almost all cells were spread on the periostin substrate (data not shown). To examine if the increase in FAK activity was dependent upon b 4 integrin interaction with periostin, the adhesion assay was conducted in presence of the anti-b 4 antibody. The data showed a significant antibody alone had no effect on phosphorylation of FAK (data not shown).
Periostin promotes the resistance of PDAC cells to hypoxia-induced cell death A recent study has shown that periostin promotes the resistance of colon carcinoma and endothelial cells to stress conditions, such as growth in the presence of the Periostin promotes invasion and survival in pancreatic cancer P Baril et al hypoxia-mimetic desferrioxamine, serum deprivation and anoikis . As pancreatic cancer is characterized by severe hypoxia and nutrient deprivation (Koong et al., 2000; Akakura et al., 2001) we sought to determine whether periostin could promote the resistance to death of PDAC cells under these tumour-relevant conditions. CFPac1 and Panc1 cells were grown under hypoxic conditions (1% O 2 ) in the presence or absence of rPN and the population of surviving cells was followed using the MTT assay. As shown in Figure 6 periostin promotes the resistance of CFPac1 cells (Figure 6a , top panel) and Panc1 cells (Figure 6b , top panel) to such stress conditions. Flow cytometric analysis using propidium iodine and annexin V indicated that periostin promoted resistance of tumour cells by delaying apoptosis (Figure 6a and b, bottom panels).
Periostin induces the phosphorylation of AKT through activation of the PI3 kinase pathway Having demonstrated that periostin promotes the phosphorylation of FAK through its interaction with b 4 integrin, we looked at the activity of AKT following treatment with periostin. CFPac1 cells were stressed by growth in hypoxic conditions for 2 days and then treated with rPN. Results from Western-blot analysis show an increasing level of AKT phosphorylation after 60 min of treatment, becoming maximal after 90 min (Figure 7a ) while the total amount of AKT remained unchanged. Treatment of cells with an IgG control antibody or with the anti-b 4 antibody alone had no effect on phosphorylation of AKT.
To identify the cell signalling pathway activated by periostin, we examined the effect of pharmacological inhibitors of the PI3K/AKT and RAF/MEK/ERK pathways on AKT phosphorylation. As shown in Figure 7b , the effect of periostin on AKT phosphorylation was completely abrogated when cells were pretreated with either LYP29002 or wortmanin but not with the PD98059 inhibitor. Moreover, treatment of pre-stressed CFPac1 cells with periostin did not change the basal level of phosphorylation of ERK. In contrast, periostin activated the p85 subunit of the PI3K complex as an elevated phosphorylation level of the p85 protein was detected after 60 min of periostin treatment (Figure 7c) . Altogether, these results suggest that phosphorylation of AKT induced by periostin was exclusively PI3 kinasedependent. Interestingly, pre-treatment of cells with the blocking anti-b 4 antibody almost completely abrogated both the phosphorylation of the p85 subunit of the PI3K complex and AKT demonstrating that the interaction of periostin with b 4 integrin is a key upstream event in this signalling pathway. Treatment of cells with an IgG control antibody or with the anti-b 4 antibody alone had no effect on phosphorylation of the p85 subunit of PI3K (data not shown).
Discussion
In this study, we report the expression and functional characterization of periostin in pancreatic ductal adenocarcinoma. We show that periostin is overexpressed in the majority of PDAC tissues as well as the sera of patients with PDAC. Periostin promotes invasiveness of PDAC cells by stimulating motility and the activation of FAK without inducing the expression of proteases or their inhibitors. Treatment of PDAC cells with periostin enhances resistance of cells to hypoxia-induced cell (Tyr397) analysed by Western-blot with a phosphospecific antibody. Antibody against the total fraction of FAK was used as loading control. Each experiment was performed at least three times in duplicate and *P-values o0.05 were considered as significant.
Periostin promotes invasion and survival in pancreatic cancer P Baril et al death, a tumour-relevant stress condition. At the molecular level, we show evidence that the b 4 integrin subunit and hence the a 6 b 4 integrin complex acts as the cell surface receptor of periostin in PDAC cells and that such interaction promotes activation of FAK and AKT via activation of the PI3 kinase pathway but not the RAS/MEK/ERK pathway. Altogether these findings strongly support the key role of periostin in PDAC progression by facilitating the adhesion, migration and survival of pancreatic tumour cells. By in situ hybridisation, we identified the tumour cells as the unique source of production of periostin while immunohistochemical analysis demonstrates the presence of periostin only in the juxtatumoral stroma. This is the first report where stromal localization of periostin is described as previous studies have reported localization of periostin in the cytoplasm of other types of cancer cells (Gillan et al., 2002; Bao et al., 2004; Shao et al., 2004; Kim et al., 2005; Tai et al., 2005) . Although, we have occasionally detected a cytoplasmic immunoreactivity of periostin in PDAC cells, the stromal Figure 6 Periostin promotes survival of CFPac1 and Panc1 cells grown under hypoxic conditions. CFPac1 (a) and (b) cells were grown in serum-free medium containing 1 g/l glucose and incubated under hypoxic conditions (1% O 2 ) in the absence (NT: not treated) or presence of periostin (PN: 5 mg/ml). The medium was changed every 36 h and the survival of cells was compared over a period of 4 days using the MTT assay (left panel). Apoptosis of cells after three days of treatment was investigated by flow cytometry analysis using Propidium Iodine and Annexin V double staining (right panel). The mean of cells in each quadrant is displayed. Each experiment was performed at least three times in duplicate. *P-values o0.05 were considered as significant. localization was always dominant. The pattern of localization of periostin in the tumoral stroma appears typically fibrillar and branched suggesting a possible association between periostin and the fibres of the desmoplastic stroma of PDAC. Recently immunoelectron microscopy analysis of mouse periodontal ligament revealed a close association between periostin and collagen fibres (Kii et al., 2006) suggesting that a same association could take place in PDAC tissues.
The spatial localization of periostin in juxtatumoral stroma exhibits similarities to other secreted proteins, such as SPARC, thrombospondin, osteopontin and tenascin-C which, once secreted, bind to extracellular matrix proteins mainly collagen type I and IV, fibronectin and laminin. These proteins, usually referred as matricellular proteins, though not being structurally related, regulate similar biological functions during embryonic development, tissue injury and cancer development mainly by promoting adhesion, migration and survival of cells (Bornstein and Sage, 2002) . While absent in almost all normal healthy adult tissues, expression of SPARC for example is restored in many cancer types (Framson and Sage, 2004) and it has been demonstrated that SPARC overexpression is correlated with an increase in invasiveness and survival of cancer cells (Rich et al., 2003; Shi et al., 2004) . Therefore, based on the important similarities between SPARC and periostin in terms of expression in the desmoplastic tumoral stroma and their common stimulatory effects on the invasion and survival of tumour cells, our results suggest that periostin could act in a similar manner as other matricellular proteins by facilitating the development and progression of pancreatic cancer. It is now generally accepted that tumour cells modify the composition of the adjacent stroma by secreting their own extracellular matrix proteins to create a permissive and supportive environment for their growth (Bissell and Radisky, 2001; Koninger et al., 2004) . This hypothesis is supported by the observation that periostin transcription is upregulated in pulmonary smooth muscle cells exposed to hypoxic conditions (Li et al., 2004) , in damaged myocardial tissues where migration and resistance of cells to apoptosis is essential (Lindner et al., 2005; Litvin et al., 2005) and in the area around developing teeth where intense cell traction and cell stress occur (Rios et al., 2005) . Altogether, these data demonstrate that gain of adhesive interaction induced by overexpression of periostin through the desmoplastic stroma should confer to the cancer cells a selective advantage during the metastatic process and suggest that periostin could be considered as a new member of the matricellular family.
At the mechanistic level, we showed that an antibody directed against b 4 integrin significantly inhibits the biological function of periostin, indicating that the a 6 b 4 integrin complex could be the cellular receptor for periostin in PDAC cells. These results are corroborated by the observation that the interaction between astrocytoma cells and big-h3, a protein homologue of periostin, is dependent on a 6 b 4 integrin (Kim et al., 2003) . Previous studies reported that the a v b 3 and a v b 5 integrin complexes act as the receptors for periostin in breast, colon and ovarian cancer as well as endothelial cells (Gillan et al., 2002; Bao et al., 2004; Shao et al., 2004) . These two integrin complexes are however not expressed in the majority of pancreatic tumour cell lines in vitro (data not show) and only 50% of PDAC tissue specimens express detectable levels of a v b 3 in vivo (Hall et al., 1991; Hosotani et al., 2002) . In contrast, the a 6 b 4 integrin complex is overexpressed in the majority of PDAC cell lines in vitro (data not shown) and pancreatic cancers tissues in vivo (Gleason et al., 2005) . The functional role of a 6 b 4 is correlated with its ability to promote the migration and survival of carcinoma cells via activation of the PI3 kinase pathway and is both dependent and independent on its interaction with laminin substrates (Lipscomb and Mercurio, 2005) . Therefore, the observation that periostin promotes phosphorylation of AKT after binding to a 6 b 4 and activation of the PI3 kinase pathway is well correlated with the role of this integrin receptor in metastatic spread of carcinoma cells. Moreover, the a 6 b 4 integrin complex is found upregulated in cancer cells under hypoxic conditions (Yoon et al., 2005) . The PI3K-AKT signalling pathway is commonly activated in PDAC due to the mutation of K-ras and PTEN genes (Hruban et al., 2000; Stoll et al., 2005) . These mutations constitutively activate several protein kinases including AKT, which plays a critical role in the control of tumour cell survival. In the present study, we show that periostin induces enhanced phosphorylation of AKT even in cells with K-ras mutations (and hence in conditions where the AKT pathway has some level of constitutive activation). One recent study reported that the use of a chemical inhibitor of AKT/PKB or overexpression of PTEN was sufficient to block the effect of periostin in promoting the resistance of colon cancer cells to stress conditions . In the present study, we have identified the exact cell-signalling pathway regulated by periostin that promotes the migration and resistance of PDAC cells to stress conditions. We demonstrate that Erk, the upstream target of RAF/MEK/ERK pathway was not activated upon interaction between periostin and the a 6 b 4 integrin complex in contrast to the p85 protein of PI3 complex which exhibited an elevated tyrosine phosphorylation level. This observation suggested that the signalling pathway mediated by periostin was acting through the PI3K/AKT pathway rather than through the RAF/ MEK/ERK pathway. However, our results do not exclude the possibility that K-Ras could contribute to periostin signalling by directly activating the PI3K complex (Rodriguez-Viciana et al., 1994) .
In conclusion, our results provide a more comprehensive picture on role of periostin in tumour progression and indicate for the first time that overexpression of periostin in pancreatic cancer is highly prevalent. Secretion of periostin through the desmoplastic stroma is predicted to facilitate the anchorage, motility and survival of PDAC cells. We demonstrate that periostin exerts its biological function via binding to a 6 b 4 which in turn activates the PI3 kinase pathway leading to the phosphorylation of the well-known survival factor AKT. These findings, correlated with the detection of periostin in serum samples of patients with pancreatic cancer, suggest a potential clinical use of periostin as a marker of malignant disease and indicate that the development of therapeutic approaches directed against periostin may be warranted for this aggressive cancer. 
Materials and methods
Tissues and cell lines
QRT-PCR and RT-PCR
The QRT-PCR and RT-PCR were conducted as described previously (Dowen et al., 2005) . The primers used for the QRT-PCR were: forward 5 0 -CAGTTTTGCCCATTGAC CATG-3 0 and reverse 5 0 -ATAGCGCTGCGTTGTGGTG-3 0 and amplified a 71 bp amplicon. For RT-PCR the primers forward 5 0 -ATGATTCCCTTTTTACCCATG-3 0 and reverse 5 0 -ACTCGGTGCAAAGTAAGTGA-3 0 used amplify a PCR product of 400 bp. The b-actin gene primers were from Invitrogen (Carlsbad, CA, USA) and used as an internal control to normalize the amount of mRNA loaded in all RT-PCR reactions.
Generation of recombinant periostin protein
Periostin cDNA (Accession Number NM_00647, OriGene Technologies, Rockville, MD, USA) was subcloned in the pFastBac vector in frame with a 6 Â His tag sequence and used to transform DH10Bac Escehrichia coli containing a baculovirus shuttle vector. Virus particles harbouring periostin cDNA were prepared according the manufacturer's instructions ('Bac-to-Bac' baculovirus expression system, Invitrogen Corp). Recombinant periostin protein was produced from 1.5 l of SF9 cells grown in suspension and infected for 5 days with high titre viral stock at a multiplicity of infection of 2.5. Cell supernatant and infected cells were collected separately and the recombinant periostin protein extracted under native conditions by using Ni-NTA agarose beads used in a batch format (QIAexpressionist kit, Qiagen, Hilden, Germany). After several washes in gradient concentrations of imidazole, periostin was eluted with a 50 mM phosphate sodium buffer pH 7.6 containing 250 mM of imadazole and 10% glycerol. The periostin protein was concentrated and the elution buffer exchanged to PBS with a 30 kDa Centricon Filter unit (Microsep, Amicon, Danvers, MA, USA).
Sandwich-ELISA assay
The sandwich-ELISA assay was performed as follows: the 8H11 antibody (1:500) was used to coat 96-well Nunc plates for 24 h at 41C followed by a blocking step with 1% BSA. Serum samples (1:50) were then added to the wells for 2 h followed by addition of the rabbit anti-periostin antibody (1:750) for 90 min. Plates were washed and immune complexes revealed by addition of an affinity-purified anti-rabbit IgG peroxidase-labelled antibody (KPL, Gaithersburg, MD, USA) and the ABTS peroxidase substrate (KPL, MD, USA). After colour development, reactions were stopped by addition of peroxidase stop solution (KPL) and the absorbance read at 490 nm using an automatic ELISA reader (Neogen Europe, Ayr, UK). Negative controls included the incubation of wells without serum samples and/or without the 8H11 monoclonal antibody.
Western blot and immunoprecipitation
For detection of the secreted form of periostin, the conditioned media of cells were concentrated and analysed by western-blot with the anti-periostin polyclonal antibody (1:10 000). To detect intracellular proteins, the cells were lysed on ice in prechilled lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 20 mM sodium fluoride, 2 mM sodium orthovanadate, 20 mM sodium pyrophosphate) containing a cocktail of protease inhibitors (Roche Diagnostics GmbH).
Immunoprecipitation was conducted by lysing the cells with pre-chilled lysis buffer and by preclearing 150 mg of cell lysate. The pre-cleared lysates were then incubated with 3 mg of antip85 PI3 Kinase antibody for 2 h at 41C followed by addition of 50 ml of ProteinG-Agarose beads for 45 min. The beads were washed 3 times with the lysis buffer and the proteins eluted for 5 min at 1001C with 1 volume of Laemmli buffer and finally analysed by western blot with the anti-phosphotyrosine PY20 or anti-p85 PI3 kinase antibodies.
In situ RNA hybridization and immunohistochemical analysis Primers for the preparation of the riboprobes were those used for RT-PCR. They amplified a PCR fragment from the nonconserved region located in the 5 0 of periostin cDNA. The PCR product was cloned into pCR4-TOPO (Invitrogen Corp, Carlsbad, CA, USA), verified by sequence analysis and used for the synthesis of antisense and sense riboprobes according to the manufacturer's instructions (RNA Labeling Kit, Roche Diagnostics GmbH, Penzerg, Germany).
Immunohistochemical analysis was conducted with the antiperiostin polyclonal antibody (1:2000) using the automated Ventana Discovery platform and the Ventana DAB Map kit (Ventana Medical Systems, Tucson, AZ, USA). Negative controls included incubation of the tissues without the primary antibody or with an irrelevant rabbit IgG antibody.
Invasion, migration and adhesion assays
The ECM invasion, migration and adhesion assays were performed as previously described (Boukerche et al., 2000) . Briefly, the 24-well BioCoat Matrigel invasion chambers (BD Biosciences, San Jose, MA, USA) were used to study the effect of periostin in the invasion of tumour cells (2 Â 10 5 cells/ assays) for 24 h in culture.
The migration (chemotaxis) assay was similar to the invasion assay except that the migration chambers (BioCoat Cell Culture Insert, BD Biosciences) did not contain matrigel and 5 Â 10 4 cells were loaded on the upper face of the filter. The migration assay was carried out for 16 h in culture.
Cell adhesion assays were performed by coating 1 mg of periostin or 1% (w/v) BSA on 96-well Nunc plates for 2 h at 371C. Cells (2 Â 10 4 ) were added to the coated wells at 371C for 1 h and washed before quantifying the number of adhesive cells by MTT assay.
Protease activity analysis by gelatin zymography and gene expression array Basal MMP-2 and MMP-9 activities were detected using gelatin zymography as previously described (Zhao et al., 2004) . Serum-starved cells were grown in the presence of periostin for 24 h and then supernatants were collected, precleared and concentrated before application of 10 mg of protein on a 10% Novex gel containing 0.1% gelatin (Invitrogen Corp). After the electrophoretic separation of proteins and activation of proteases on gels, the gels were Coomassie-stained and destained on appearance of white bands indicating proteolytic activities.
To determine if periostin could activate other proteases, gene expression profiling was performed using the GEArray Q series system provided by SuperArray (Frederick, MD, USA). Each array is composed of 96 known genes spotted in duplicate, of which 30 represent proteases and their inhibitors. Serum-starved cells were grown in the presence of periostin (5 mg/ml) for 18 h and then total RNA was extracted and purified. The reverse transcriptase, probe labelling, hybridization, detection and data analysis were performed according to the manufacturer's instructions (SuperArray). The expression values of each gene were normalized to b-actin and compared between the periostin-treated and control samples. An arbitrary cutoff of at least twofold difference between the groups was used.
Cell survival assay and flow cytometry analysis The effect of periostin on cell survival was tested by serumstarving the cells for 24 h before growing the cells in the presence or absence of periostin (5 mg/ml) in serum-free DMEM medium containing 1 g/l glucose (Life Technologies). Culture dishes were then placed in a hypoxic incubator at 1% O 2 and every 36 h the cells were re-fed with fresh medium. The survival of cells was quantified using the MTT assay.
For the analysis of apoptotic cells, hypoxia-stressed cells were harvested and incubated for 30 min in the dark in HEPES buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl 2 ) containing Annexin V-Alexa fluor 488 (2.5 mg/ml). A solution of propidium iodide (50 mg/ml) was added to the cells immediately before acquisition of a total of 10 4 events on a FACSCalibur cytometer and the analysis by using Cellquest software (BD Biosciences, Oxford, UK).
Statistical analysis
Each experiment was performed at least three times. Error bars represent7s.e. Student's t-tests were performed to determine statistical significance for the following assays: sandwich-ELISA, adhesion, migration, invasion and MTT.
Abbreviations PDAC, pancreatic ductal adenocarcinoma; PN, periostin; rPN, recombinant periostin protein; PMA, Phorbol 12-myristate 13-acetate; FGFa, acidic Fibroblast Growth Factor^TGFb, Transforming Growth Factor beta; PI, propidium iodine; QRT-PCR, quantitative real-time PCR; ISH, In situ mRNA hybridization.
